Eli Lilly and Company announced it will terminate the Phase 3 trial of the investigational medicine evacetrapib due to insufficient efficacy. The company will discontinue development of evacetrapib for the treatment of high-risk atherosclerotic cardiovascular disease and will now conclude other studies in the program.
"We're obviously disappointed in this outcome, as we hoped that evacetrapib would offer an advance in treatment for people with high-risk cardiovascular disease. We'll be working with investigators to appropriately conclude these trials," said David Ricks, Lilly senior vice president and president of Lilly Bio-Medicines. "We remain confident in our pipeline as we prepare for launches in other therapeutic areas with significant unmet needs."
The decision to discontinue development of evacetrapib is expected to result in a fourth-quarter charge to research and development expense of up to $90 million (pre-tax).
Read the full release